The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG^®), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT)

References

• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142–1147.
   PubMed Web of Science ®Google Scholar
• Pradaxa. 2017. Available from: https://www.boehringer-ingelheim.com/products/pradaxa
   Google Scholar
• Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47–59.
   PubMed Web of Science ®Google Scholar
• Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48:1411–1419.
   PubMed Web of Science ®Google Scholar
• Pernod G, Albaladejo P, Godier A, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) – March 2013. Arch Cardiovasc Dis. 2013;106:382–383.
   PubMed Web of Science ®Google Scholar
• Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–3562.
   PubMed Web of Science ®Google Scholar
• Na SY, Mracsko E, van Ryn J, et al. Idarucizumab improves outcome in murine brain hemorrhage related to dabigatran. Ann Neurol. 2015;78:137–141.
   PubMed Web of Science ®Google Scholar
• Pollack CV, Jr., Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015;114:198–205.
   PubMed Web of Science ®Google Scholar
• Pollack CV, Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
   PubMed Web of Science ®Google Scholar
• Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105:371–378.
   PubMed Web of Science ®Google Scholar
• Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol. 2012;159:427–429.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–1127.
   PubMed Web of Science ®Google Scholar
• Herrmann R, Thom J, Wood A, et al. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost. 2014;111:989–995.
   PubMed Web of Science ®Google Scholar
• Dinkelaar J, Patiwael S, Harenberg J, et al. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med. 2014;52:1615–1623.
   PubMed Web of Science ®Google Scholar
• Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinol. 2012;23:138–143.
   PubMed Web of Science ®Google Scholar
• Nowak G. The Ecarin Clotting Time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemos Thromb. 2003;33:173–183.
   PubMed Web of Science ®Google Scholar
• Antovic JP, Skeppholm M, Eintrei J, et al. Evaluation of coagulation assays versus LC–MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol. 2013;69:1875–1881.
   PubMed Web of Science ®Google Scholar
• Johansson PI. Goal-directed hemostatic resuscitation for massively bleeding patients: the Copenhagen concept. Transfus Apher Sci. 2010;43:401–405.
   PubMed Web of Science ®Google Scholar
• Solbeck S, Meyer MA, Johansson PI, et al. Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. Int J Cardiol. 2014;176:794–799.
   PubMed Web of Science ®Google Scholar
• Dias JD, Norem K, Doorneweerd DD, et al. Use of thromboelastography (TEG) for detection of new oral anticoagulants. Arch Pathol Lab Med. 2015;139:665–673.
   PubMed Web of Science ®Google Scholar
• Davis PK, Musunuru H, Walsh M, et al. The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine. Thromb Haemost. 2012;108:586–588.
   PubMed Web of Science ®Google Scholar
• Solbeck S, Ostrowski SR, Stensballe J, et al. Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests. Int J Cardiol. 2016;208:14–18.
   PubMed Web of Science ®Google Scholar
• Levy JH, Faraoni D, Spring JL, et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology. 2013;118:1466–1474.
   PubMed Web of Science ®Google Scholar
• Albaladejo P, Samama CM, Sie P, et al. Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis. Anesthesiology. 2017;127:111–120.
   PubMed Web of Science ®Google Scholar
• Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–328.
   PubMed Web of Science ®Google Scholar
• Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9:2168–2175.
   PubMed Web of Science ®Google Scholar
• Levi M, Hunt BJ. A critical appraisal of point-of-care coagulation testing in critically ill patients. J Thromb Haemost. 2015;13:1960–1967.
   PubMed Web of Science ®Google Scholar
• Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222.
   PubMed Web of Science ®Google Scholar